Breaking News Instant updates and real-time market news.

ETSY

Etsy

$42.45

0.88 (2.12%)

, MNK

Mallinckrodt

$24.36

0.2 (0.83%)

09:02
08/07/18
08/07
09:02
08/07/18
09:02

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Etsy (ETSY), up 13%... Mallinckrodt (MNK), up 16%... Twilio (TWLO), up 17%... NeoPhotonics (NPTN), up 10%. DOWN AFTER EARNINGS: Zilllow (ZG), down 16%... Dean Foods (DF), down 11%... Owens & Minor (OMI), down 13%. LOWER: Spark Therapeutics (ONCE), down 32% after the company announced preliminary Phase 1/2 data for its investigational gene therapy candidate SPK-8011 for hemophilia A... Protagonist Therapeutics (PTGX), down 3% after the company filed to sell 2.75M shares and warrants... TriplePoint Venture (TPVG), down 4% after a 6M share spot secondary offering priced at $13.66.

ETSY

Etsy

$42.45

0.88 (2.12%)

MNK

Mallinckrodt

$24.36

0.2 (0.83%)

TWLO

Twilio

$63.26

1.24 (2.00%)

NPTN

NeoPhotonics

$6.86

0.22 (3.31%)

ZG

Zillow

$59.04

0.89 (1.53%)

Z

Zillow

$58.18

0.6 (1.04%)

DF

Dean Foods

$9.45

-0.245 (-2.53%)

ARMK

Aramark

$38.25

-0.07 (-0.18%)

ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

PTGX

Protagonist Therapeutics

$11.10

4.08 (58.12%)

TPVG

TriplePoint Venture

$13.92

0.14 (1.02%)

  • 07

    Aug

  • 07

    Aug

  • 07

    Aug

  • 07

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 12

    Aug

  • 13

    Aug

  • 16

    Aug

  • 20

    Aug

  • 22

    Aug

  • 31

    Aug

  • 04

    Sep

  • 06

    Sep

  • 10

    Sep

  • 07

    Aug

ETSY Etsy
$42.45

0.88 (2.12%)

07/16/18
JMPS
07/16/18
NO CHANGE
JMPS
Market Perform
Etsy comments hint at possible competitive moat for Avalara, says JMP Securities
After reviewing the South Dakota v. Wayfair Supreme Court opinion and some of the related Amicus Curiae briefs, JMP Securities analyst Patrick Walravens highlighted a comment from Etsy's (ETSY) brief that concluded that "given this complexity [of mapping thousands of tax codes to millions of unique products], it is doubtful that a software fix ever can be developed." Rather than doubting that a software solution can ever be developed, Walravens said he views the complexity referenced by Etsy as the market opportunity and potential competitive moat for Avalara, he tells investors. Still, Walravens believes Avalara is currently fairly valued and maintains his Market Perform rating on the shares.
06/22/18
LOOP
06/22/18
NO CHANGE
LOOP
SCOTUS decision will not have large online retailer impact, says Loop Capital
Loop Capital analyst Laura Champine notes that yesterday's decision by the U.S. Supreme Court to overrule the 1992 Quill v. North Dakota which restricted states from requiring sales tax collection from businesses clears the way for states to require online merchants to collect sales tax from customers. The analyst believes however that any financial impact on the online retailers from this decision will be negligible and recommends that investors buy into any related weakness on Amazon (AMZN), Etsy (ETSY), and Wayfair (W).
06/21/18
KEYB
06/21/18
NO CHANGE
KEYB
Supreme Court ruling negative for Wayfair, eBay and Etsy, says KeyBanc
After the Supreme Court ruled that states can require online merchants to collect sales taxes, KeyBanc analyst Edward Yruma called the ruling a negative for Wayfair (W), arguing that it may reduce some of the price differential that has helped it gain share from traditional peers. The ruling is also a negative, but to a lesser degree, for eBay (EBAY) and Etsy (ETSY), said Yruma, who views the impact on those two as more related to compliance and implementation. He adds that the news could be a modest positive for retailers of high-ticket and branded products, such as Best Buy (BBY), Home Depot (HD), Lowe's (LOW), La-Z-Boy (LZB), Kirkland's (KIRK), RH (RH) and Williams-Sonoma (WSM).
08/06/18
LOOP
08/06/18
NO CHANGE
Target $55
LOOP
Buy
Etsy price target raised to $55 from $50 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Etsy (ETSY) to $55 and kept her Buy rating after its Q2 earnings beat and raised guidance. The analyst notes that while the stock price has already doubled year-to-date, its positive momentum is likely to continue after another update forecasting continued revenue growth. Champine also believes that her revenue growth forecasts may prove to be conservative, as Etsy's holiday promotional activity later this year is likely to increase seller count. The analyst contends that Etsy's seller fees at 5% are also an "excellent value" relative to eBay's (EBAY) 10% and Amazon's (AMZN) 15%.
MNK Mallinckrodt
$24.36

0.2 (0.83%)

06/25/18
MZHO
06/25/18
NO CHANGE
MZHO
Buy
Depomed cosyntropin opportunity may be underappreciated, says Mizuho
Mizuho analyst Irina Koffler says her physician checks give her more conviction about her thesis on Depomed (DEPO), stating that its cosyntropin opportunity may be underappreciated while investors focus on its older products. She imagines that Mallinckrodt's (MNK) Acthar may need to be discounted if the cosyntropin synthetic launches, Koffler added. She maintains a Buy rating on Depomed shares.
07/19/18
ADAM
07/19/18
NO CHANGE
Target $22
ADAM
Hold
Mallinckrodt price target raised to $22 from $14 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on Mallinckrodt to $22 from $14 after meeting with management. The company gave incrementally positive updates on its pipeline, which along with the potential sale of the generics franchise can move the story forward, he believes. The recent updates justify the recent run-up in the shares, said Steadman, who keeps his Hold rating on Mallinckrodt.
07/09/18
WELS
07/09/18
NO CHANGE
Target $21
WELS
Market Perform
Mallinckrodt price target raised to $21 from $15 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Mallinckrodt to $21 from $15 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
06/28/18
RILY
06/28/18
NO CHANGE
Target $20
RILY
Neutral
Mallinckrodt price target raised to $20 from $15 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Mallinckrodt to $20 but keeps a Neutral rating on the shares. The analyst continues to have concerns over competition and leverage.
TWLO Twilio
$63.26

1.24 (2.00%)

06/28/18
06/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Air Transport Services (ATSG) upgraded to Buy from Hold at Stifel with analyst David Ross saying shares are attractive at current levels given long-term growth prospects. 2. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche stating that recent conversations with some of his DC contacts have made him more optimistic that a deal to merge with Sprint (S) could be approved. 3. Talend (TLND) upgraded to Buy from Neutral at with analyst Tyler Radke saying a survey of Chief Data Officers shows "strong spending signals" while the company's competitive backdrop is favorable amid "increasing cloud tailwinds". 4. Regions Financial (RF) upgraded to Neutral from Underperform at Baird with analyst David George citing the recent pullback, which he thinks has made the valuation more reasonable. 5. Twilio (TWLO) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the pullback in the stock price has created a more favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
ADAM
08/07/18
NO CHANGE
Target $80
ADAM
Buy
Twilio price target raised to $80 from $52 at Canaccord
Canaccord analyst Richard Davis raised his price target on Twilio to $80 from $52 following Q2 results that showed upside on every metric he tracks. He noted the company turned profitable one quarter earlier than expected, guidance was very strong, and its Flex program continues to show early traction. Davis reiterated his Buy rating on Twilio shares.
08/07/18
BARD
08/07/18
NO CHANGE
Target $82
BARD
Outperform
Twilio price target raised to $82 from $50 at Baird
Baird analyst William Power raised his price target on Twilio to $82 from $50 following the company's "blow-out" Q2 results. The analyst also noted the raised guidance on the heels of its stronger than expected quarter and he sees multiple drivers supporting it in the second half of the year. Power reiterated his Outperform rating on Twilio shares.
08/07/18
JPMS
08/07/18
NO CHANGE
Target $75
JPMS
Overweight
Twilio price target raised to $75 from $60 at JPMorgan
JPMorgan analyst Mark Murphy raised his price target for Twilio to $75 saying the company last night posted an "outstanding" Q2 with "substantial improvement in its growth-plus-margin profile, cementing its performance in the top echelon of the software industry." Total revenue accelerated to 54% year-over-year growth and was 13% above consensus, Murphy tells investors in a post-earnings research note. The analyst reaffirms Twilio as a top SMID-cap pick and keeps an Overweight rating on the shares.
NPTN NeoPhotonics
$6.86

0.22 (3.31%)

04/25/18
NEED
04/25/18
NO CHANGE
NEED
Full ban of sales to Huawei 'highly improbable,' says Needham
Needham analysts Alex Henderson and N. Quinn Bolton said they sees the chances of an outright ban of sales to Huawei as "extremely low," adding that it is their understanding the probe into Huawei has been ongoing for the last two years while noting that the ZTE probe took over five years to complete. The ironic impact of any escalation in trade tension could be an increase in demand from Huawei to build an inventory buffer should there be a supply disruption, added the analysts, who also say they would not be surprised to see a trade agreement with China include a resolution of the ZTE (ZTCOY) ban and possibly an agreement on the scope of action against Huawei.
05/21/18
NEED
05/21/18
NO CHANGE
NEED
Oclaro filing hints NeoPhotonics may have started sale process, says Needham
Needham analyst Alex Henderson said the S-4 filed by Lumentum (LITE) related to its deal to acquire Oclaro (OCLR) shows that the latter looked to make an acquisition and that company rejected the offer as insufficient but has "started a sell process." Henderson believes this unidentified company is most likely NeoPhotonics (NPTN), he tells investors. He also noted that the S-4 shows another bidder other than Lumentum offered $9 per share in cash for Oclaro, which he believes is likely Finisar (FNSR), adding that "this potential Oclaro acquirer would likely be interested in NeoPhotonics, in our opinion."
07/18/18
PIPR
07/18/18
NO CHANGE
PIPR
Piper 'incrementally more upbeat' on Optical sector into earnings
Piper Jaffray analyst Troy Jensen is "incrementally more upbeat" on the Optical sector and believes investors "need to revisit the group" ahead of the June quarter earnings results. The set up for traditional optical component suppliers has improved with the industry now five quarters into the correction that started in March 2017, Jensen tells investors in a research note. This has created easy comps while growth rates should accelerate in the second half of 2018, the analyst adds. His favorite Overweight-rated names are Lumentum (LITE), II-VI (IIVI) and Fabrinet (FN). Jensen remains Neutral on Applied Optoelectronics (AAOI), Acacia Communications (ACIA), Infinera (INFN), NeoPhotonics (NPTN) and Oclaro (OCLR).
08/07/18
RILY
08/07/18
UPGRADE
Target $10
RILY
Buy
NeoPhotonics upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Dave Kang upgraded NeoPhotonics to Buy and raised his price target for the shares to $10 from $6.50. The analyst sees improving fundamentals and increased his estimates following the company's Q2 results.
ZG Zillow
$59.04

0.89 (1.53%)

08/07/18
JEFF
08/07/18
NO CHANGE
Target $52
JEFF
Hold
Zillow price target lowered to $52 from $60 at Jefferies
Jefferies analyst Brent Thill lowered his price target for Zillow to $52 saying that while the Q2 results were inline, the "shocker" came from the company reducing fiscal guidance in three of its five businesses, or Homes, Rentals, Other. The guidance revisions highlight the company's near-term forecasting issues rather than a fundamental flaw in the business, Thill tells investors in a post-earnings research note titled "Over their Water Ski Tips." The analyst continues to await a better entry point before getting more constructive on Zillow shares.
08/07/18
DADA
08/07/18
NO CHANGE
Target $52
DADA
Neutral
Zillow price target lowered to $52 from $57 at DA Davidson
DA Davidson analyst Tom White lowered his price target on Zillow to $52 and kept his Neutral rating after its Q2 results, saying that while its Premier Agent and Mortgages units topped expectations, Rentals and other IMT segment revenues disappointed. White states that Zillow's Homes segment saw the biggest impact toward the downside revision of the overall revenue outlook, while its profitability forecast was also driven lower by its incremental headcount needs. The analyst also notes that the weakness in Rentals was surprising, with the company prioritizing the long-term product improvements over near-term traffic performance and lead generation.
08/07/18
RBCM
08/07/18
NO CHANGE
Target $46
RBCM
Sector Perform
Zillow price target lowered to $46 from $52 at RBC Capital
RBC Capital analyst Mark Mahaney lowered his price target on Zillow to $46 and kept his Sector Perform rating after its in-line Q2 results and reduced revenue/EBITDA outlook for its core IMT segment and new Homes unit in FY18. The analyst also points to the company's acquisition of Mortgage Lenders in reducing his estimates.
08/07/18
BNCH
08/07/18
NO CHANGE
Target $60
BNCH
Buy
Zillow likely down 20% at open after 'miss and lower' report, says Benchmark
Benchmark analyst Daniel Kurnos said Zillow (ZG) missed quarter results and lowered full-year guidance for "the firm time in recent history," leading him to expect the stock to likely be down about 20% on the open following its Q2 report. However, the fact that is guidance does not include expected revenue from the Mortgage Lenders of America acquisition, as well as international expansion plans, give him some hope that the company is back to being conservative with its outlook, Kurnos tells investors. The analyst, who is optimistic that increased seller leads will help continue to drive IMT EBITDA growth of over 30%, keeps a Buy rating on Zillow but lowered his price target on the stock to $60 from $62.
Z Zillow
$58.18

0.6 (1.04%)

08/07/18
KEYB
08/07/18
NO CHANGE
Target $56
KEYB
Overweight
Zillow price target lowered to $56 from $63 at KeyBanc
KeyBanc analyst Brad Erickson lowered his price target for Zillow to $56 from $63 while reiterating an Overweight rating on the shares. The analyst believes the company's lowered guidance and mortgage origination acquisition create significant noise that should hit the stock, but thinks the company remains best positioned to capture more profit from the real estate transaction through added utility as it explores new ways to move down funnel.
06/18/18
06/18/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Redfin (RDFN) was downgraded to Sell from Neutral at Goldman Sachs while Zillow (Z, ZG) was downgraded to Neutral from Buy. 2. Dun & Bradstreet (DNB) downgraded to Neutral from Outperform at Baird with analyst Jeffrey Meuler saying he believes any potential take-out is already priced into the shares, the current valuation seems to limit potential upside, and the business requires more substantial changes to return it to sustainable organic growth. 3. Hibbett Sports (HIBB) downgraded to Underperform from Buy at BofA/Merrill analyst Rafe Jadrosich saying he expects negative same-store-sales declines in Q4 and continuing through 2020 as Hibbett laps the ecommerce launch and excess inventory clearance. 4. Cheesecake Factory (CAKE) downgraded to Neutral on valuation at BTIG with analyst Peter Saleh citing recent share strength. 5. Intel (INTC) downgraded to Underperform from Market Perform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DF Dean Foods
$9.45

-0.245 (-2.53%)

05/14/18
05/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dean Foods (DF) downgraded to Sell from Hold at Deutsche Bank analyst Rob Dickerson saying he still sees four fundamental challenges facing the company: continued declines in U.S. dairy milk consumption, its low-margin structured business, increasing vertical category integration by retailers, and what he views as low odds of transformative acquisitions. 2. Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Stephen East saying his outlook for Roofing and Composites has weakened and extremely weak year to date 2018 hail/storm activity is likely an incremental headwind to 2H18 Shingle Volumes while inflationary cost pressures are more intense than originally expected. 3. Xerox (XRX) downgraded to Neutral from Overweight at JPMorgan and to Hold from Buy at Cross Research. 4. Jeld-Wen (JELD) downgraded to Neutral from Buy at BofA/Merrill with analyst John Lovallo saying he believes the company will face challenges from the CEO search, Steves & Sons litigation, wood windows, and believes a margin recovery could take longer than expected. 5. Hostess Brands (TWNK) downgraded to Hold from Buy at Deutsche Bank with analyst Rob Dickerson saying he is less certain on the base business' potential margin and profitability progression over the next twelve months following the company's recent earnings report. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
05/14/18
DOWNGRADE
Target $9

Sell
Dean Foods downgraded to Sell following rally at Deutsche Bank
As previously reported, Deutsche Bank analyst Rob Dickerson downgraded Dean Foods to Sell from Hold after the stock rallied 25% since the company's Q1 earnings report about a week ago, saying he still sees four fundamental challenges facing the company - continued declines in U.S. dairy milk consumption; its low-margin structured business; increasing vertical category integration by retailers; and what he views as low odds of transformative acquisitions. Dickerson raised his price target on Dean Foods shares to $9 from $8.
05/14/18
DBAB
05/14/18
DOWNGRADE
DBAB
Sell
Dean Foods downgraded to Sell from Hold at Deutsche Bank
04/16/18
04/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. McDonald's (MCD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying he believes the mid-single-digit comp growth of recent quarters should not be considered the norm. 2. J.M. Smucker (SJM) downgraded to Underperform from Neutral at Credit Suisse with analyst Robert Moskow saying he believes that while the company has leading brands in two big, growing categories, the dynamic changes in consumer preferences have significantly devalued or commoditized its legacy brands and impaired its competitiveness. 3. Dean Foods (DF) downgraded to Sell from Neutral at Goldman Sachs. 4. Dollar General (DG), Dollar Tree (DLTR), and Big Lots (BIG) were downgraded to Outperform from Strong Buy at Raymond James. 5. Crocs (CROX) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes its wholesale mid-single digit growth may not be sustainable for the next few years despite an expected acceleration of the sandal business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ARMK Aramark
$38.25

-0.07 (-0.18%)

01/24/18
FBCO
01/24/18
INITIATION
Target $50
FBCO
Outperform
Aramark reinstated with an Outperform at Credit Suisse
Credit Suisse analyst Anjaneya Singh reinstated coverage of Aramark with an Outperform rating and $50 price target after coming off restriction related to the AmeriPride deal.
01/24/18
01/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Valeant (VRX) initiated with a Sell at Goldman Sachs. 2. trivago (TRVG) initiated with a Hold at SunTrust. 3. Holly Energy (HEP) initiated with a Hold at Jefferies. 4. Aramark (ARMK) reinstated with an Outperform at Credit Suisse. 5. The Medicines Co. (MDCO) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/18
JPMS
04/17/18
NO CHANGE
Target $50
JPMS
Overweight
Aramark pullback brings buying opportunity, says JPMorgan
JPMorgan analyst Andrew Steinerman believes the recent pullback in shares of Aramark presents a buying opportunity. The company's "self-help" margin expansion opportunity, combined with its "solid track" record on margins should yield "compelling results" this year, Steinerman tells investors in a research note. The analyst points out that the shares have underperformed the market by 14% since the Q1 results on February 6. He keeps an Overweight rating on the name with a $50 price target.
06/19/18
MSCO
06/19/18
NO CHANGE
Target $42
MSCO
Equal Weight
Morgan Stanley cuts Q3 estimates for Aramark on lower baseball attendance
Noting that industry-wide baseball attendance is down 6.7% through June 14, and that attendance has declined by 9.5% at Aramark's 10 stadiums, Morgan Stanley analyst Toni Kaplan lowered her Q3 consolidated organic growth estimate for Aramark to 2.6% from 3.3%. She keeps a $42 price target and Equal Weight rating on Aramark shares.
ONCE Spark Therapeutics
$77.63

3.84 (5.20%)

07/19/18
RBCM
07/19/18
DOWNGRADE
Target $75
RBCM
Sector Perform
Spark Therapeutics cut to Sector Perform at RBC Capital on SPK-801 concern
As reported earlier, RBC Capital analyst Kennen MacKay downgraded Spark Therapeutics to Sector Perform from Outperform and kept his $75 price target. The analyst notes that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." McKay also cites the possibility of regulatory delays to gain approval for sale of Luxturna among the risks for Spark Therapeutics.
07/16/18
CANT
07/16/18
NO CHANGE
Target $103
CANT
Overweight
Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald
After Spark Therapeutics (ONCE) announced that partner Pfizer (PFE) initiated a Phase 3 study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, Cantor Fitzgerald analyst Elemer Piros said he was encouraged that the program transfer is on track and he remains bullish on the fidanacogene elaparvovec program. He reiterates his Overweight rating and $103 price target on Spark shares.
07/19/18
RBCM
07/19/18
DOWNGRADE
RBCM
Sector Perform
Spark Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
07/19/18
07/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Hold at Needham with analyst Rajvindra Gill saying the stock remains overvalued in spite of its 16% decline from the the June 2017 peak. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at UBS with analyst Steven Strycula saying the company's reinvestment cycle limits earnings and stock upside. 3. Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying his crane check was good but not great, with demand appearing to sequentially flatten. 4. Spark Therapeutics (ONCE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Kennen MacKay saying that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." 5. Hyatt (H) downgraded to Hold from Buy at Berenberg with analyst El Kassir saying Hyatt continues to benchmark well on its pipeline, however, there is little scope for future growth to accelerate from current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PTGX Protagonist Therapeutics
$11.10

4.08 (58.12%)

08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist Therapeutics' PTG-100 'back on track,' says Leerink
Leerink analyst Joseph Schwartz says PTG-100 in Ulcerative colitis is "back on track," increasing his confidence in Protagonist Therapeutics' peptide technology platform. The analyst notes that the company reported this morning an unexpected, but very positive, turnaround of its lead program, PTG-100, and will now pursue late-stage clinical development, assuming a positive discussion with the FDA occurs in 2H. While it is unfortunate that the program lost some time when the data set was initially mis-scored and deemed futile when in fact today's news suggests that PTG-100 could have robust clinical efficacy, Schwartz believes that Protagonist's persistence to uncover the truth leading to the resuscitation of the program is positive. The analyst reiterates an Outperform rating on the stock and raised his price target on the shares to $21 from $13.
08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist price target raised to $21 after study re-analysis at Leerink
Leerink analyst Joseph P. Schwartz raised his price target on Protagonist Therapeutics shares to $21 from $13 after the company announced results from an independent blinded re-analysis of the Phase 2 PROPEL study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment of patients with ulcerative colitis. He maintains an Outperform rating on Protagonist shares.
06/06/18
LEHM
06/06/18
DOWNGRADE
Target $8.5
LEHM
Equal Weight
Protagonist downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Protagonist Therapeutics to Equal Weight and lowered his price target for the shares to $8.50 from $30. The analyst continues to see value in the company's pipeline assets, but does expect achievement of key catalysts until the second half of 2019. As such, the analyst sees greater near-term potential in small cap names with catalysts upcoming, such as Foamix (FOMX).
03/27/18
BMOC
03/27/18
NO CHANGE
Target $13
BMOC
Outperform
Protagonist Therapeutics price target lowered to $13 from $42 at BMO Capital
BMO Capital analyst M. Ian Somaiya slashed his price target on Protagonist Therapeutics (PTGX) to $13 following the announcement that the company is discontinuing its Phase 2b study of PTG-100 in patients with moderate to severe ulcerative colitis. Somaiya adds that his valuation is now driven by the risk-adjusted sales model for PTG-200, which "represents a higher probability clinical program with peak sales of over $2B". The analyst also notes that he continues to exclude the clinical data of PTG-300 from his model. Despite the steep price target revision, Somaiya keeps his Outperform rating and recommends that investors buy into the weakness after the PTG-100 clinical disappointment on anticipated PTG-200 data and the advancement of Johnson&Johnson (JNJ) - shared Stelara.
TPVG TriplePoint Venture
$13.92

0.14 (1.02%)

11/28/17
COMP
11/28/17
UPGRADE
COMP
Buy
TriplePoint Venture upgraded to Buy from Neutral at Compass Point
08/06/18
08/06/18
NO CHANGE

TriplePoint Venture announces public offering of 6M shares and private placement
TriplePoint Venture announced that it has commenced an underwritten offering of 6,000,000 shares of its common stock, concurrently with the proposed public offering, it has agreed to sell 200,000 shares of common stock through a private placement to certain affiliates of Colony Capital, Inc. Additionally certain accounts managed by Goldman Sachs Asset Management, L.P. are required to purchase 200,000 shares pursuant to a prior agreement with the Company Morgan Stanley, Wells Fargo Securities, Goldman Sachs & Co. LLC, J.P. Morgan and Keefe, Bruyette & Woods, A Stifel Company, are acting as joint book-running managers for the proposed Public Offering. Deutsche Bank Securities is acting as lead manager for the proposed Public Offering.
04/16/18
KBWI
04/16/18
INITIATION
Target $13
KBWI
Market Perform
TriplePoint Venture initiated with a Market Perform at Keefe Bruyette
Keefe Bruyette started TriplePoint Venture Growth BDC with a Market Perform rating and $13 price target.
11/28/17
11/28/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Home Depot (HD) upgraded to Overweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the U.S. housing backdrop remains strong and recent hurricanes should provide a tailwind through the first half of 2018, at the very least. 2. TCF Financial (TCF) was upgraded to Overweight from Neutral at Piper Jaffray and to Buy from Hold at Sandler O'Neill. 3. Popular (BPOP) and OFG Bancorp (OFG) were upgraded to Outperform from Market Perform at Keefe Bruyette. 4. Mellanox (MLNX) upgraded to Equal Weight from Underweight at Barclays with analyst Joseph Wolf saying he believes activist Starboard can bring upon change and will serve as a "positive technical element to near-term stock performance." 5. TriplePoint Venture (TPVG) upgraded to Buy from Neutral at Compass Point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WMT

Walmart

$97.89

-0.74 (-0.75%)

13:37
08/18/18
08/18
13:37
08/18/18
13:37
Periodicals
Walmart asks beauty suppliers to consider sourcing outside of China, Reuters say »

Walmart has asked some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

13:26
08/18/18
08/18
13:26
08/18/18
13:26
Periodicals
Tencent-backed Qutoutiao files for U.S. IPO, Reuters reports »

Chinese content…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

13:10
08/18/18
08/18
13:10
08/18/18
13:10
Periodicals
Selloff in Chinese internet stocks may shake faith in FANG, Reuters says »

A steep downturn in…

FB

Facebook

$173.78

-0.98 (-0.56%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

NFLX

Netflix

$316.78

-5.51 (-1.71%)

GOOG

Alphabet

$1,199.79

-6.21 (-0.51%)

GOOGL

Alphabet Class A

$1,215.50

-8.05 (-0.66%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

VLKAY

Volkswagen

$0.00

(0.00%)

13:05
08/18/18
08/18
13:05
08/18/18
13:05
Periodicals
Volkswagen CEO was told about emissions software months before, Reuters reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, TCEHY

Tencent

$0.00

(0.00%)

13:01
08/18/18
08/18
13:01
08/18/18
13:01
Hot Stocks
Walmart, Flipkart announce completion of investment »

Walmart (WMT) and…

WMT

Walmart

$97.89

-0.74 (-0.75%)

TCEHY

Tencent

$0.00

(0.00%)

MSFT

Microsoft

$107.58

-0.07 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

BBOX

Black Box

$1.64

0.09 (5.81%)

12:57
08/18/18
08/18
12:57
08/18/18
12:57
Hot Stocks
Black Box announces sale agreement of Federal Government IT Services Business »

Black Box announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$76.43

1.68 (2.25%)

12:52
08/18/18
08/18
12:52
08/18/18
12:52
Periodicals
Kohl's looking to break cycle, Barron's says »

Kohl's is set to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

STT

State Street

$84.95

0.73 (0.87%)

12:47
08/18/18
08/18
12:47
08/18/18
12:47
Periodicals
State Street selloff looks overdone, Barron's says »

At the moment, State…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$97.89

-0.74 (-0.75%)

, AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

12:42
08/18/18
08/18
12:42
08/18/18
12:42
Periodicals
May be time to sell Walmart, Barron's says »

In a follow-up story,…

WMT

Walmart

$97.89

-0.74 (-0.75%)

AMZN

Amazon.com

$1,881.94

-5.56 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

VZ

Verizon

$54.79

0.51 (0.94%)

12:39
08/18/18
08/18
12:39
08/18/18
12:39
Periodicals
Verizon remains 'reasonably' priced, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CF

CF Industries

$47.52

0.25 (0.53%)

, MOS

Mosaic

$29.64

(0.00%)

12:36
08/18/18
08/18
12:36
08/18/18
12:36
Periodicals
CF, Mosaic gains have just begun, Barron's says »

CF Industries (CF),…

CF

CF Industries

$47.52

0.25 (0.53%)

MOS

Mosaic

$29.64

(0.00%)

NTR

Nutrien

$55.95

0.94 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 06

    Nov

ABBV

AbbVie

$98.79

0.6 (0.61%)

, LYB

LyondellBasell

$113.07

1.155 (1.03%)

12:25
08/18/18
08/18
12:25
08/18/18
12:25
Periodicals
StAbbVie, Starbucks among dividend standouts, Barron's says »

AbbVie (ABBV),…

ABBV

AbbVie

$98.79

0.6 (0.61%)

LYB

LyondellBasell

$113.07

1.155 (1.03%)

AVGO

Broadcom

$209.27

0.6 (0.29%)

RF

Regions Financial

$19.48

0.09 (0.46%)

SBUX

Starbucks

$53.58

0.53 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 11

    Sep

  • 12

    Sep

  • 12

    Sep

BV

BrightView

$17.49

-0.06 (-0.34%)

12:21
08/18/18
08/18
12:21
08/18/18
12:21
Periodicals
Sunny outlook for BrightView, Barron's says »

BrightView's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

, CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

11:18
08/18/18
08/18
11:18
08/18/18
11:18
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HOG

Harley-Davidson

$42.26

1.15 (2.80%)

CSIQ

Canadian Solar

$13.12

0.02 (0.15%)

FSLR

First Solar

$50.98

0.18 (0.35%)

JASO

JA Solar

$0.00

(0.00%)

SUNEQ

SunEdison

$0.00

(0.00%)

SPWR

SunPower

$6.65

0.06 (0.91%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

PEP

PepsiCo

$114.98

0.7 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:10
08/17/18
08/17
17:10
08/17/18
17:10
Hot Stocks
Boeing awarded $152.5M U.S. Navy contract »

Boeing is awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:09
08/17/18
08/17
17:09
08/17/18
17:09
Hot Stocks
Boeing awarded $217M Defense Department contract »

The Boeing Co has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$210.37

0.56 (0.27%)

17:08
08/17/18
08/17
17:08
08/17/18
17:08
Hot Stocks
L3 Technologies awarded $240M Defense Department contract »

L-3 Communications was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSGX

Histogenics

$2.65

-0.05 (-1.85%)

17:06
08/17/18
08/17
17:06
08/17/18
17:06
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$67.45

1.79 (2.73%)

, DCT

DCT Industrial

$68.77

1.805 (2.70%)

16:58
08/17/18
08/17
16:58
08/17/18
16:58
Conference/Events
DCT Industrial to host special shareholder meeting »

Special Shareholder…

PLD

Prologis

$67.45

1.79 (2.73%)

DCT

DCT Industrial

$68.77

1.805 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.